HBIO
Price
$0.44
Change
-$0.00 (-0.00%)
Updated
Sep 26 closing price
Capitalization
19.77M
40 days until earnings call
MLSS
Price
$0.46
Change
-$0.01 (-2.13%)
Updated
Sep 26 closing price
Capitalization
36.14M
46 days until earnings call
Interact to see
Advertisement

HBIO vs MLSS

Header iconHBIO vs MLSS Comparison
Open Charts HBIO vs MLSSBanner chart's image
Harvard Bioscience
Price$0.44
Change-$0.00 (-0.00%)
Volume$245.77K
Capitalization19.77M
Milestone Scientific
Price$0.46
Change-$0.01 (-2.13%)
Volume$73.32K
Capitalization36.14M
HBIO vs MLSS Comparison Chart in %
Loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HBIO vs. MLSS commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Buy and MLSS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (HBIO: $0.44 vs. MLSS: $0.46)
Brand notoriety: HBIO and MLSS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: HBIO: 30% vs. MLSS: 16%
Market capitalization -- HBIO: $19.77M vs. MLSS: $36.14M
HBIO [@Pharmaceuticals: Other] is valued at $19.77M. MLSS’s [@Pharmaceuticals: Other] market capitalization is $36.14M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $158.13B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileMLSS’s FA Score has 0 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • MLSS’s FA Score: 0 green, 5 red.
According to our system of comparison, HBIO is a better buy in the long-term than MLSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 2 TA indicator(s) are bullish while MLSS’s TA Score has 4 bullish TA indicator(s).

  • HBIO’s TA Score: 2 bullish, 6 bearish.
  • MLSS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, MLSS is a better buy in the short-term than HBIO.

Price Growth

HBIO (@Pharmaceuticals: Other) experienced а -5.27% price change this week, while MLSS (@Pharmaceuticals: Other) price change was -11.32% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.13%. For the same industry, the average monthly price growth was -3.06%, and the average quarterly price growth was +8.48%.

Reported Earning Dates

HBIO is expected to report earnings on Nov 06, 2025.

MLSS is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLSS($36.1M) has a higher market cap than HBIO($19.8M). MLSS YTD gains are higher at: -52.083 vs. HBIO (-78.962). MLSS has higher annual earnings (EBITDA): -6.83M vs. HBIO (-46.8M). HBIO has more cash in the bank: 7.44M vs. MLSS (1.27M). MLSS has less debt than HBIO: MLSS (1.09M) vs HBIO (43.3M). HBIO has higher revenues than MLSS: HBIO (88.8M) vs MLSS (9.08M).
HBIOMLSSHBIO / MLSS
Capitalization19.8M36.1M55%
EBITDA-46.8M-6.83M685%
Gain YTD-78.962-52.083152%
P/E RatioN/AN/A-
Revenue88.8M9.08M978%
Total Cash7.44M1.27M584%
Total Debt43.3M1.09M3,983%
FUNDAMENTALS RATINGS
HBIO vs MLSS: Fundamental Ratings
HBIO
MLSS
OUTLOOK RATING
1..100
8151
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
9195
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLSS's Valuation (98) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that MLSS’s stock grew similarly to HBIO’s over the last 12 months.

MLSS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that MLSS’s stock grew similarly to HBIO’s over the last 12 months.

MLSS's SMR Rating (99) in the Medical Specialties industry is in the same range as HBIO (99) in the Biotechnology industry. This means that MLSS’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's Price Growth Rating (91) in the Biotechnology industry is in the same range as MLSS (95) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to MLSS’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for MLSS (100) in the Medical Specialties industry. This means that HBIO’s stock grew significantly faster than MLSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIOMLSS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 24 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMPH26.850.49
+1.86%
Amphastar Pharmaceuticals
WELL174.903.20
+1.86%
Welltower
IGC0.400.01
+1.77%
IGC Pharma
AXSM116.760.75
+0.65%
Axsome Therapeutics
XPOF7.850.03
+0.38%
Xponential Fitness

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
+1.07%
IRMD - HBIO
51%
Loosely correlated
+2.51%
SGHT - HBIO
39%
Loosely correlated
+1.46%
A - HBIO
38%
Loosely correlated
+1.23%
TMO - HBIO
35%
Loosely correlated
+1.09%
MTD - HBIO
35%
Loosely correlated
-0.42%
More

MLSS and

Correlation & Price change

A.I.dvisor tells us that MLSS and ANGO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MLSS and ANGO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLSS
1D Price
Change %
MLSS100%
-1.69%
ANGO - MLSS
28%
Poorly correlated
+0.85%
ESTA - MLSS
26%
Poorly correlated
N/A
PRE - MLSS
26%
Poorly correlated
+2.11%
KRMD - MLSS
25%
Poorly correlated
+1.02%
HBIO - MLSS
25%
Poorly correlated
+1.07%
More